CA2584702A1 - Nitrobenzindoles and their use in cancer therapy - Google Patents

Nitrobenzindoles and their use in cancer therapy Download PDF

Info

Publication number
CA2584702A1
CA2584702A1 CA002584702A CA2584702A CA2584702A1 CA 2584702 A1 CA2584702 A1 CA 2584702A1 CA 002584702 A CA002584702 A CA 002584702A CA 2584702 A CA2584702 A CA 2584702A CA 2584702 A1 CA2584702 A1 CA 2584702A1
Authority
CA
Canada
Prior art keywords
indole
dihydro
benzo
chloromethyl
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002584702A
Other languages
English (en)
French (fr)
Inventor
William Alexander Denny
William Robert Wilson
Ralph James Stevenson
Moana Tercel
Graham John Atwell
Shangjin Yang
Adam Vorn Patterson
Frederik Bastiaan Pruijn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2584702A1 publication Critical patent/CA2584702A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings
    • C07F9/5728Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/60Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CA002584702A 2004-10-22 2005-10-21 Nitrobenzindoles and their use in cancer therapy Abandoned CA2584702A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ536107A NZ536107A (en) 2004-10-22 2004-10-22 Nitrobenzindoles and their use in cancer therapy
NZNZ536107 2004-10-22
PCT/NZ2005/000278 WO2006043839A1 (en) 2004-10-22 2005-10-21 Nitrobenzindoles and their use in cancer therapy

Publications (1)

Publication Number Publication Date
CA2584702A1 true CA2584702A1 (en) 2006-04-27

Family

ID=36203204

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002584702A Abandoned CA2584702A1 (en) 2004-10-22 2005-10-21 Nitrobenzindoles and their use in cancer therapy

Country Status (14)

Country Link
US (1) US7718688B2 (https=)
EP (1) EP1809603A4 (https=)
JP (1) JP2008517905A (https=)
KR (1) KR20070083806A (https=)
CN (1) CN101044114B (https=)
AU (1) AU2005296389B2 (https=)
BR (1) BRPI0517285A (https=)
CA (1) CA2584702A1 (https=)
IL (1) IL182652A0 (https=)
MX (1) MX2007004596A (https=)
NZ (1) NZ536107A (https=)
RU (1) RU2007118938A (https=)
WO (1) WO2006043839A1 (https=)
ZA (1) ZA200703699B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1994000B1 (en) * 2006-02-02 2017-08-23 Syntarga B.V. Water-soluble cc-1065 analogs and their conjugates
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
US8076491B2 (en) 2007-08-21 2011-12-13 Senomyx, Inc. Compounds that inhibit (block) bitter taste in composition and use thereof
KR101558193B1 (ko) 2007-08-21 2015-10-12 세노믹스, 인코포레이티드 인간 t2r 쓴맛 수용체 및 이의 용도
NZ571028A (en) * 2008-09-03 2011-01-28 Auckland Uniservices Ltd Nitrobenzindole compounds and their use in cancer treatment
AU2009320481C1 (en) 2008-11-03 2016-12-08 Syntarga B.V. Novel CC-1065 analogs and their conjugates
AU2011243294C1 (en) 2010-04-21 2015-12-03 Syntarga B.V. Novel conjugates of CC-1065 analogs and bifunctional linkers
CN102827061A (zh) * 2012-09-19 2012-12-19 兰州大学 5,6,7-三甲氧基吲哚类衍生物、制备方法及用途
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
AU2015205574B2 (en) 2014-01-10 2019-08-15 Byondis B.V. Method for purifying Cys-linked antibody-drug conjugates
HUE029672T2 (en) 2014-01-10 2017-03-28 Synthon Biopharmaceuticals Bv Duokarmicin-ADCs for use in the treatment of endometrial cancer
CN105899236B (zh) 2014-01-10 2019-07-26 斯索恩生物制药有限公司 表现出改进的体内抗肿瘤活性的倍癌霉素adc
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
JPWO2019004413A1 (ja) * 2017-06-30 2020-05-07 東レ株式会社 インドリン誘導体及びそれを含む細胞毒性剤
CN112724068A (zh) * 2020-12-30 2021-04-30 蔡桂坡 具有hdac抑制活性的吲哚类衍生物的合成方法及肿瘤应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ334344A (en) 1996-09-12 2000-08-25 Cancer Res Campaign Tech benzo[e]indole and pyrrolo[3,2-e]indole compounds and their use as prodrugs
JP4862120B2 (ja) * 2001-02-22 2012-01-25 ユニヴァーシティ オブ ブラッドフォード 腫瘍治療のためのプロドラッグとしてのベンズ−インドールおよびベンゾ−キノリン誘導体
WO2003097635A1 (en) * 2002-05-17 2003-11-27 Auckland Uniservices Limited Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3h-[ring fused indol-5-yl(amine-derived)] compounds and analogues thereof, and to products obtained therefrom
NZ529249A (en) 2003-10-31 2006-04-28 Auckland Uniservices Ltd Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic

Also Published As

Publication number Publication date
NZ536107A (en) 2007-06-29
US7718688B2 (en) 2010-05-18
US20080119442A1 (en) 2008-05-22
BRPI0517285A (pt) 2008-10-07
EP1809603A1 (en) 2007-07-25
JP2008517905A (ja) 2008-05-29
CN101044114B (zh) 2012-02-15
CN101044114A (zh) 2007-09-26
AU2005296389A1 (en) 2006-04-27
AU2005296389B2 (en) 2012-03-15
EP1809603A4 (en) 2009-09-02
WO2006043839A1 (en) 2006-04-27
IL182652A0 (en) 2007-07-24
KR20070083806A (ko) 2007-08-24
RU2007118938A (ru) 2008-11-27
MX2007004596A (es) 2007-06-22
ZA200703699B (en) 2008-10-29

Similar Documents

Publication Publication Date Title
CA2584702A1 (en) Nitrobenzindoles and their use in cancer therapy
US6130237A (en) Condensed N-aclyindoles as antitumor agents
AU721037B2 (en) Condensed N-acylindoles as antitumor agents
EP1948242B9 (en) Cytotoxic compounds
KR101596526B1 (ko) Parp 억제제 화합물, 조성물 및 사용 방법
CA2382317C (en) Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
CA2758904C (en) Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
AU2007246850B2 (en) Pentacyclic indole derivatives as antiviral agents
JP6568926B2 (ja) 癌の治療のためのerbbチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体
AU2020356793B2 (en) PH/glutathione-responsive β-carbolines/cycloketene derivatives and their preparation and application
CA2229264A1 (en) Cyclopropylindoles and their seco precursors, and their use as prodrugs
ES2441115T3 (es) Derivados de CBI sujetos a activación reductora
WO2000064864A9 (en) N-protected amines and their use as prodrugs
JP2008517905A5 (https=)
US20050148651A1 (en) Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3h-[ring fused indol-5-yl-(amine- derived)] compounds and analogues thereof, and to products obtained therefrom
US20070191372A1 (en) Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy
CA2575269A1 (en) Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents
ES2652444T3 (es) Análogos de diazonamida
Lee et al. Optimised synthesis of a nitroCBI hypoxia-activated prodrug with substantial anticancer activity
Lee et al. Auckland Cancer Society Research Centre, School of Medical Sciences, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
WO2026041623A1 (en) Metal complex compounds, conjugates and conjugatable compounds therefrom as well as uses thereof and processes of producing the same
PL219085B1 (pl) Pochodne 5,11-dimetylo-5H-indolo[2,3-b]chinoliny, sposób ich otrzymywania i środek farmaceutyczny zawierający pochodną 5,11-dimetylo-5H-indolo[2,3-b]chinoliny
CA3209234A1 (en) Heteroaromatic phosphonium salts and their use treating cancer
JPH08151380A (ja) ビス(トリフルオロメチルピロロインドールカルボン酸エステル)誘導体及びその製造方法
TW202241890A (zh) 表皮生長因子受體之抑制劑

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140620